



# CPVT: The Only Thing that Scares me in the Inherited Arrhythmia Clinic

Andrew Krahn MD FHRS

Sauder Family and Heart and Stroke Foundation Chair in Cardiology
Paul Brunes Chair in Heart Rhythm Disorders
University of British Columbia Vancouver Canada

President Elect, Heart Rhythm Society







## Conflict of Interest

none



https://heartsinrhythm.ca










I am an open access person – for slides, e mail <a href="mail.ubc.ca"><u>akrahn@mail.ubc.ca</u></a>

(I will repeat that at the end)


## Case Presentation

- 21 year old female Triathlete
- Palpitations while swimming, lightheaded
- Gets out of pool and has syncope
- Awakens after 10 seconds, heart pounding
- Gets up, LOC again
- No previous events
- Sister with SIDS at 2 months
- Dutch heritage






# Resting ECG



## Investigations


- Echo normal
- MRI LV normal
  - ? RV dilatation
  - at most 1 minor criteria for ARVC
  - Normal coronary arteries




- **SUMMARY** 1. Normal left ventricular dimensions, wall thickness and systolic function. The LV ejection fraction is 58%.
  - 2. The right ventricle is borderline enlarged when indexed to body surface area. There is regional wall thinning in the right ventricular outflow tract that is assocaited with hypokinesia. A small microaneurysm is also noted. Normal global systolic function with an ejection fraction of 60%. There is prominent trabeculation along the right ventricular free wall.
  - 3. No evidence of intramyocardial fat or edema.
  - 4. Non-specific mild fibrosis of the RV insertion site in the inferospetal wall.
  - Normal atrial dimensions.
  - No significant valvular heart disease.

Overall, there are sufficient RV findings to classify a minor criterion for the diagnosis of a right ventricular cardiomyopathy (ARVC). There is no evidence of any other non-ischemic cardiomyopathic process that could explain the presenting arrhythmia. The coronary arteries are normal in origin and course.

## Exercise Test




## **Exercise Test**




## Catecholaminergic Polymorphic Ventricular Tachycardia CPVT


- Mendelian cause of adolescent exertional syncope and cardiac arrest
- Causative genetic variant identified in ~60% of cases
  - RyR2 gain-of-function
  - CASQ2 (rare)
  - TECRL (ultra-rare)
- Established therapies:
  - Beta-blocker
  - Flecainide
  - Left cardiac sympathectomy
  - ICD (probably not!)



## **CPVT**

- Intracellular Ca<sup>++</sup> overload
- Exercise/swimming induced syncope / SCD
- Hallmark rhythm is bidirectional VT






# CPVT is an important cause of SCA & SCD in young people with a structurally normal heart

#### Perfect electrical assassin:


- Fainting history common in general population
- Children with CPVT are often the first in their family to be diagnosed
- de novo variants are common
- Normal ECG
- Normal ECHO
- Low use of stress test



## High Probability of Symptoms



Symptom free survival in CPVT



## Fainting


- History is the key
  - The syncope of CPVT is not usually during expected intense exertion
- It is possible to have both a benign common faint and also have a life-threatening condition
- Most faints do not need the emergency department or a genetic cardiologist review
- Red flags: drowning, mid-activity faint, positive family history



## Diagnostic Advances: Exercise Testing

#### "BURST" exercise test?


- Start the ETT at highest stage reached on Bruce
  - 6 patients, in 5 the Burst induced more arrhythmias than the Bruce
- Multicenter evaluation ongoing, to determine if:
  - Can unmask worst VE
  - Can confirm suppression on therapy
  - Can diagnose unexplained adrenergic VF event



## Diagnostic Advances: Atrial Phenotype

Original PACES retrospective registry showed 22% of children had atrial arrhythmia

• Genetic and prognostic importance of atrial arrhythmia not known



■ No atrial arrhythmia ■ AF ■ AFL ■ AT ■ AVNRT

#### Mayo Clinic experience

- 10 of 127 pts had AA (8%)
- 80% were symptomatic from AA, including syncope
- Medical therapy appeared to usually work

Kowgli et al. Heart Rhythm 2020: D-AB17-04

## Treatment


#### **PATIENT**

- Beta blockers
  - Nadolol
- Flecainide
- Cardiac denervation
- Lifestyle modifications
  - Education
  - Safety plan



#### **FAMILY & COMMUNITY**

- Family screening
- Safety plan
  - CPR & AED
  - Don't stop the betablocker for low heart rates!



## Therapeutic Advances: **\beta-blockers**

- Combined Int'l and Pediatric registries
  - 329 symptomatic CPVT children followed for 6.6 yrs (median)
  - Compared types and classes of  $\beta$ -blockers and risk of LTE in follow-up
  - Non-selective better than selective
  - Nadolol probably best
  - Breakthrough events 39% non adherent,
     24% under dosed
  - 4 deaths

Peltenburg et al. Circulation. 2022;145:333






Figure 3. Clinical Course of Patients With RYR2 Catecholaminergic Polymorphic Ventricular Tachycardia During  $\beta$ -Blocker Therapy Only



A, Kaplan-Meier estimate of cumulative survival free from the first life-threatening arrhythmic events (LTAEs) in  $\beta$ -blocker therapy only shows the cumulative probability of experiencing a first catecholaminergic polymorphic ventricular tachycardia while taking  $\beta$ -blocker therapy was 2.4% (95% CI, 0.3%-4.5%), 9.3% (95% CI, 4.8%-13.6%), and 20.8% (95% CI, 12.9%-28.0%) at 1, 5, and 10 years of follow-up, respectively. B, Kaplan-Meier estimate of cumulative survival free from the first LTAE stratified by time-varying type of principal  $\beta$ -blocker used demonstrates that the cumulative probability of experiencing a first LTAE while taking  $\beta$ -blocker therapy only was 26.2% (95% CI, 9.7%-39.8%), 10.0% (95% CI, 0.0%-22.9%), and 1.0% (95% CI, 0%-3.0%) at 5 years of follow-up for selective  $\beta$ -blockers, propranolol, and nadolol, respectively.

## Recommendations for Safe Sports in CPVT



Believe it or not, exercise training may be protective in CPVT!


✓ Get an Expert **Evaluation** 



✓ Ensure swimming is supervised



✓ Plan for emergency





✓ Take medications as prescribed



Stay **hydrated** 



Manotheepan et al. Cardiovasc Res, 2016





#### Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest

```
Christian van der Werf<sup>1</sup>*†, Krystien V. Lieve<sup>1</sup>†, J. Martijn Bos<sup>2,3,4</sup>,
Conor M. Lane<sup>2,3,4</sup>, Isabelle Denjoy<sup>5‡</sup>, Ferran Roses-Noguer (b) <sup>6</sup>, Takeshi Aiba<sup>7</sup>, Yuko Wada (b) <sup>8</sup>, Jodie Ingles (b) <sup>9,10,11</sup>, Ida S. Leren (b) <sup>12</sup>, Boris Rudic <sup>13,14</sup>,
Peter J. Schwartz (b) 15‡, Alice Maltret (b) 16, Frederic Sacher 17,
Jonathan R. Skinner (b) 18,19, Andrew D. Krahn (b) 20, Thomas M. Roston (b) 20,21,22,
Jacob Tfelt-Hansen<sup>23</sup>, Heikki Swan<sup>24</sup>, Tomas Robyns (b) <sup>25‡</sup>, Seiko Ohno<sup>8,26</sup>,
Jason D. Roberts<sup>27</sup>, Maarten P. van den Berg<sup>28</sup>, Janneke A. Kammeraad<sup>29</sup>,
Vincent Probst<sup>30‡</sup>, Prince J. Kannankeril (1) <sup>31</sup>, Nico A. Blom<sup>32,33</sup>,
Elijah R. Behr (1) 34,35‡, Martin Borggrefe 13,14, Kristina H. Haugaa 12,
Christopher Semsarian<sup>9,10,11</sup>, Minoru Horie (1) <sup>8</sup>, Wataru Shimizu<sup>7,36</sup>,
Janice A. Till<sup>6</sup>, Antoine Leenhardt<sup>5‡</sup>, Michael J. Ackerman<sup>2,3,4¶</sup>, and
Arthur A. Wilde (1) 1,37‡¶
```

#### Conclusion

In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival. Instead, the ICD was associated with both a high rate of appropriate ICD shocks and inappropriate ICD shocks along with other device-related complications. Strict adherence to guideline-directed therapy without an ICD may provide adequate protection in these patients without all the potential disadvantages of an ICD.


## Calcium Release Deficiency Syndrome

JAMA Cardiology | Original Investigation

## Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome

Thomas M. Roston, MD, PhD; Jinhong Wei, PhD; Wenting Guo, PhD; Yanhui Li, MD, PhD; Xiaowei Zhong, PhD; Ruiwu Wang, PhD; John Paul Estillore, MD; Puck J. Peltenburg, MD; Ferran Rosés I. Noguer, MD; Jan Till, MD; Lee L. Eckhardt, MD, MS; Kate M. Orland, MS; Robert Hamilton, MD; Martin J. LaPage, MD, MS; Andrew D. Krahn, MD; Rafik Tadros, MD, PhD; Jeffrey M. Vinocur, MD; Dania Kallas, MSc; Sonia Franciosi, PhD; Jason D. Roberts, MD, MAS; Arthur A. M. Wilde, MD, PhD; Henrik K. Jensen, MD, DMSc, PhD; Shubhayan Sanatani, MD; S. R. Wayne Chen, PhD

Figure 1. Summary of Ryanodine Receptor 2 (RyR2)–Calcium-Release Deficiency Syndrome (CRDS) Case Ascertainment and Outcomes in the Multicenter Cohort




#### LOF variants:

- Q2275H
- E4451del
- F4499C
- V4606E
- R4608Q
- R4608W

Roston & Wei et al. JAMA Cardiol 2021

## Benign Polymorphic VT?



#### Benign variant?

- 5 middle aged males (age 52±5 yrs)
- Incidental detection of PVCs on health check
- Negative family history, structurally normal heart
- Limited genetics negative
- Suppressed with beta blocker

#### Conclusions

- CPVT is a rare treatable cardiac channelopathy
- Diagnosis is likely enabled by burst exercise testing
- Breakthrough events on optimal treatment are very infrequent
- Safe sports following guidelines should be encouraged with shared decision making
- Our basic science colleagues have a lot to contribute





I am an open access person – for slides, e mail <u>akrahn@mail.ubc.ca</u>